- Home
- COOT vs CGTX Comparison
COOT vs CGTX Comparison
Compare COOT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOT
- CGTX
- Stock Information
- Founded
- COOT 2020
- CGTX 2007
- Country
- COOT Australia
- CGTX United States
- Employees
- COOT N/A
- CGTX N/A
- Industry
- COOT
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- COOT
- CGTX Health Care
- Exchange
- COOT NYSE
- CGTX Nasdaq
- Market Cap
- COOT 23.0M
- CGTX 26.8M
- IPO Year
- COOT N/A
- CGTX 2021
- Fundamental
- Price
- COOT $1.27
- CGTX $0.41
- Analyst Decision
- COOT
- CGTX Strong Buy
- Analyst Count
- COOT 0
- CGTX 6
- Target Price
- COOT N/A
- CGTX $7.50
- AVG Volume (30 Days)
- COOT 8.6K
- CGTX 659.3K
- Earning Date
- COOT 01-01-0001
- CGTX 03-20-2025
- Dividend Yield
- COOT N/A
- CGTX N/A
- EPS Growth
- COOT N/A
- CGTX N/A
- EPS
- COOT N/A
- CGTX N/A
- Revenue
- COOT $21,517,422.00
- CGTX N/A
- Revenue This Year
- COOT N/A
- CGTX N/A
- Revenue Next Year
- COOT N/A
- CGTX N/A
- P/E Ratio
- COOT N/A
- CGTX N/A
- Revenue Growth
- COOT 16.10
- CGTX N/A
- 52 Week Low
- COOT $0.61
- CGTX $0.34
- 52 Week High
- COOT $1.69
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- COOT 40.11
- CGTX 40.25
- Support Level
- COOT $1.20
- CGTX $0.41
- Resistance Level
- COOT $1.34
- CGTX $0.44
- Average True Range (ATR)
- COOT 0.08
- CGTX 0.04
- MACD
- COOT -0.01
- CGTX 0.00
- Stochastic Oscillator
- COOT 43.84
- CGTX 27.42
About COOT AUSTRALIAN OILSEEDS HOLDINGS LTD
Australian Oilseeds Holdings Ltd through its subsidiaries, is focused on the manufacture and sale of chemical-free, non-GMO, sustainable edible oils and products derived from oilseeds. The company believes that transitioning from a fossil fuel economy to a renewable and chemical-free economy is the solution to many health problems the world is facing presently.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.